Royalty Pharma (RPRX) Common Equity (2019 - 2026)

Royalty Pharma has disclosed Common Equity across 8 years of filings, most recently posting $9.9 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $9.9 billion, up 1.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.9 billion (up 1.63% YoY), and the FY2025 annual result was $9.7 billion, down 6.07% from the prior year.
• Common Equity came in at $9.9 billion for Q1 2026 at Royalty Pharma, up from $9.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.4 billion in Q3 2022 to a low of $9.5 billion in Q2 2025.
• The 5-year median for Common Equity is $9.8 billion (2023), against an average of $9.9 billion.
• Across the five-year window, Common Equity fell 7.98% in 2023 and rose 7.03% in 2024, its largest moves.
• Royalty Pharma's Common Equity stood at $9.5 billion in 2022, then gained by 5.87% to $10.1 billion in 2023, then gained by 2.56% to $10.3 billion in 2024, then retreated by 6.07% to $9.7 billion in 2025, then grew by 2.28% to $9.9 billion in 2026.
• The last three Common Equity figures came in at $9.9 billion (Q1 2026), $9.7 billion (Q4 2025), and $9.6 billion (Q3 2025), per Business Quant data.